Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2025 –2032 | |
|
|
USD 47.38 Billion |
| USD 195.75 Billion | |
| % | |
|
Global Lung Cancer Screening Software Market Segmentation, By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions, and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management, and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender and Third Party Distributors) - Industry Trends and Forecast to 2032
|
Attributes
|
Lung Cancer Screening Software Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
North America
Europe
Asia-Pacific
Middle East and Africa
South America
|
|
Key Market Players
|
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
|
“AI-Powered Diagnostic Precision and Workflow Automation”
Driver
“Growing Need Due to Rising Lung Cancer Incidence and AI Adoption”
Restraint/Challenge
“Concerns Regarding Data Security and High Implementation Cost”
The market is segmented on the basis of mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel.
On the basis of mode of delivery, the market is segmented into cloud-based solutions, on-premise solutions, and web-based solutions. The cloud-based solutions segment dominates with the largest market revenue share in 2024, driven by its scalability, cost-efficiency, and ability to enable real-time data sharing across multiple healthcare facilities, supporting large-scale screening programs.
The web-based solutions segment is expected to witness the fastest growth during the forecast period due to its accessibility via any internet-enabled device without the need for complex installations, making it attractive for smaller clinics and outpatient centers focusing on flexible deployment and ease of use.
On the basis of product, the market includes lung cancer screening radiology solutions, patient management software, nodule management software, data collection and reporting, patient coordination and workflow, lung nodule computer-aided detection (CAD), pathology and cancer staging, statistical audit reporting, screening PACS, practice management, and audit log tracking. The lung cancer screening radiology solution segment dominates the market in 2024, fueled by its critical role in enhancing imaging accuracy and early tumor detection through integration with AI algorithms.
Meanwhile, the nodule management software segment is projected to be the fastest growing, due to rising clinical focus on longitudinal monitoring of lung nodules to guide timely intervention and improve patient outcome
On the basis of type, the market is segmented into computer-assisted screening and traditional screening. The computer-assisted screening segment holds the dominant share in 2024, supported by rapid advancements in AI-driven image analysis and risk prediction models that significantly improve diagnostic accuracy and reduce false positives.
The traditional screening segment, is expected to grow steadily as legacy systems continue in use in less technologically advanced regions, with gradual digital upgrades offering new opportunities for hybrid screening models.
On the basis of application, the market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The NSCLC segment dominates with a large market share of 85.5% in 2024, owing to the higher global incidence rate of NSCLC and greater emphasis on screening programs targeting high-risk populations such as smokers.
The SCLC segment is expected to experience the fastest growth rate during the forecast period, driven by increasing research investments and the development of novel screening protocols aimed at improving early detection despite the cancer’s aggressive progression.
On the basis of platform, the market is segmented into standalone and integrated platforms. The integrated platform segment dominates in 2024, supported by its ability to connect seamlessly with hospital information systems (HIS), radiology information systems (RIS), and PACS, streamlining workflows and improving clinician collaboration
The standalone platform segment is projected to grow at the fastest rate during the forecast period, due to its cost-effectiveness, ease of deployment, and suitability for smaller healthcare providers and emerging markets where comprehensive integration is less feasible.
On the basis of purchase mode, the market is segmented into institutional and individual purchases. The institutional purchase segment dominated the market in 2024 due to large healthcare facilities, oncology centers, and hospitals acquiring advanced, scalable solutions to manage high patient volumes and comply with screening guidelines.
The individual purchase segment is anticipated to witness the fastest growth during the forecast period, driven by smaller clinics and private practices investing in affordable and user-friendly software options to provide localized screening and diagnostics
On the basis of end user, the market is segmented into oncology centers, hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2024, as hospitals house comprehensive diagnostic infrastructure and multidisciplinary teams required for large-scale lung cancer screening.
The ambulatory surgical centers segment is expected to register the fastest growth during the forecast period, fueled by their rising adoption of outpatient diagnostic services, convenience, and cost-effectiveness for patients, enabling expanded lung cancer screening coverage beyond traditional hospital settings.
On the basis of distribution channel, the market is segmented into direct tender and third-party distributors. The direct tender segment dominates due to hospitals and large institutions preferring direct procurement to customize solutions and ensure compliance with local regulations and support requirements.
The third-party distributors segment is expected to witness the fastest CAGR from 2025 to 2032, as distributors play a crucial role in emerging markets by providing localized sales, technical support, and training, helping software providers penetrate new regions and smaller healthcare facilities more effectively.
U.S. Lung Cancer Screening Software Market Insight
The U.S. lung cancer screening software market captured the largest revenue share in 2024 within North America, driven by widespread adoption of advanced diagnostic technologies and rising awareness of lung cancer screening benefits. Increasing integration of AI-powered imaging tools and cloud-based platforms enhances diagnostic accuracy and workflow efficiency. Growing initiatives to promote early lung cancer detection among high-risk populations, such as smokers, are further propelling market growth. In addition, strong healthcare infrastructure and high healthcare expenditure support the adoption of sophisticated lung cancer screening solutions.
Europe Lung Cancer Screening Software Market Insight
The Europe lung cancer screening software market is expected to grow steadily at a notable CAGR throughout the forecast period, supported by increasing healthcare digitization and regulatory emphasis on early cancer detection. The region's rising investment in healthcare IT infrastructure and growing adoption of AI in medical imaging bolster market expansion. Moreover, national screening programs in countries such as the UK, Germany, and France are accelerating the use of lung cancer screening software. The emphasis on interoperability and data privacy standards further shapes software development and deployment in Europe.
U.K. Lung Cancer Screening Software Market Insight
The U.K. lung cancer screening software market is projected to expand significantly, driven by government-led screening initiatives and increased public health awareness. The NHS's focus on lung health and preventive care encourages the integration of computer-assisted screening tools in diagnostic pathways. Adoption of cloud-based and AI-enhanced screening software is rising, supported by robust digital health policies and a well-established healthcare IT ecosystem. In addition, growing collaboration between healthcare providers and technology firms fosters innovation and market growth.
Germany Lung Cancer Screening Software Market Insight
The Germany’s lung cancer screening software market is expected to witness strong growth, underpinned by increasing healthcare digitization and investments in AI-driven diagnostics. The country’s advanced healthcare system and commitment to precision medicine drive adoption of lung cancer screening software across hospitals and specialized centers. Emphasis on data security and compliance with stringent EU regulations promotes the development of secure, reliable software solutions. The integration of screening software with hospital information systems is also a key growth factor
Asia-Pacific Lung Cancer Screening Software Market Insight
The Asia-Pacific lung cancer screening software market is poised to grow at the fastest CAGR from 2025 to 2032, fueled by rising healthcare expenditure, expanding healthcare infrastructure, and growing awareness about lung cancer. Rapid urbanization and increasing government initiatives for cancer screening, particularly in China, India, and Japan, support market expansion. Technological advancements, including AI and cloud computing, are accelerating adoption in the region. In addition, improving affordability and increasing private healthcare investments further drive market growth.
Japan Lung Cancer Screening Software Market Insight
The Japan’s lung cancer screening software market is gaining momentum due to a high aging population and widespread adoption of digital healthcare solutions. The emphasis on early diagnosis and integration of AI-powered screening tools enhances market growth. Japan's robust healthcare infrastructure and government support for advanced medical technologies facilitate rapid adoption. The market also benefits from strong collaborations between healthcare providers and tech companies, focusing on improving screening accuracy and patient management.
India Lung Cancer Screening Software Market Insight
The India accounted for the largest market revenue share in Asia-Pacific in 2024, driven by rapid urbanization, increasing lung cancer incidence, and growing awareness of early detection benefits. The expanding middle class and improving healthcare infrastructure boost adoption of lung cancer screening software, especially in urban centers. Government programs promoting cancer awareness and screening initiatives support market growth. In addition, affordable software solutions and partnerships with domestic technology providers enable penetration into tier-2 and tier-3 cities.
The lung cancer screening software industry is primarily led by well-established companies, including:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.